Product pipeline

XG-102

In 2011 and 2012, Xigen completed a Phase I in Switzerland as well as a Phase Ib clinical trial in France.
In 2013 a phase II multicenter study in the field of Ophthalmology was completed in Europe. In August 2014 and in July 2015, two phase III studies (in Ophthalmology) were started in the US, they were completed in 2015 and 2016.
In parallel, a Phase II multicentric clinical trial with XG-102 has been completed in Europe by its partner Auris Medical, a Swiss based company targeting ear disorders.

XG-104

In 2014, Xigen successfully completed two Phase I studies in France. A Phase II study in ophthalmology started in the US in August 2014 and was completed in 2015.